The QualityStocks Daily Friday, July 24th, 2020

Today's Top 3 Investment Newsletters

StockMarketWatch (NTZ) +54.59%

MarketClub Analysis (ENT) +53.81%

QualityStocks (SHMP) +39.94%

The QualityStocks Daily Stock List

First Vanadium Corp. (FVANF)

Geology for Investors, Barchart, Dividend Investor, Simply Wall St, Stock Gumshoe, Stockchase, OTC Markets, PR Newswire, Investor Ideas, Wallet Investor, InvestorX, Resource World, Stockwatch, Investors Hangout, Central Charts, Stockhouse, TalkMarkets, TMXmoney, Stock News Now, Northern Miner, Streetwise Reports, Mining Feeds, OTC.Watch, Metals News, Junior Mining Network, Canadian Mining Journal, InvestorsHub, Morningstar, and Investing News reported previously on First Vanadium Corp. (FVANF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

First Vanadium Corp. engages in the acquisition, exploration, evaluation, and development of mineral properties in the USA and Canada. It explores for copper, silver, zinc, and gold minerals. The Company’s Board, Management, and Technical Team is an assembled group of experienced, respected, and successful explorers, mine builders, as well as mine operators.

The Company previously went by the name Cornerstone Metals, Inc. It changed its name to First Vanadium Corp. in September of 2018. Incorporated in 2006, First Vanadium is headquartered in Vancouver, British Columbia. The Company lists on the OTC Markets Group’s OTCQB.

First Vanadium has an option to earn a 100 percent interest in the Carlin Vanadium Project, positioned in Elko County, 6 miles south from the town of Carlin, Nevada, and Highway I-80. The Carlin Vanadium Property comprises 150 unpatented mining claims and 80 acres of fee simple land encompassing 2,608 acres. The Carlin Vanadium Project hosts the Carlin Vanadium deposit that is flat to shallow dipping and at shallow depths with a strike length of about 1,800 meters, width averaging 600 meters, and thickness ranging from 15 meters to 50 meters.

In addition, First Vanadium has its West Jerome Property. The focus of this Property is in the copper-rich district of Arizona, near the Town of Jerome, Central Arizona. First Vanadium owns 100 percent (subject to 1.5 percent NSR) of the West Jerome property, on the south side of Freeport McMoRan patented lands.

The Property lies in a Volcanogenic Massive Sulfide (VMS) camp. The West Jerome Property is a high-grade, massive sulfide target positioned 2.4 km south of the past-producing United Verde (32 million tons grading 4.4 percent copper, 1.5 oz/t silver and 0.04 oz/t gold).

In June, First Vanadium announced the filing of a technical report prepared in accordance with National Instrument 43-101, Standards of Disclosure for Mineral Projects (NI 43-101) concerning the Preliminary Economic Assessment (PEA) for its Carlin Vanadium Project. The PEA demonstrates positive economics for a large-scale open pit mining operation, with 16 years of Vanadium production and 4 additional years of acid/power sales. The PEA is available under First Vanadium's profile on SEDAR at www.sedar.com.

On July 9, 2020, First Vanadium announced that it completed the closing of its non-brokered private placement earlier announced on June 18, 2020 and increased on June 26, 2020. It has issued 10,666,667 units for gross proceeds of $1,600,000. All securities issued are subject to a four month hold period expiring November 10, 2020. Furthermore, First Vanadium awarded the drill contract to drill-test the gold opportunity on the Carlin Vanadium Project.

Mr. Paul Cowley, First Vanadium's Chief Executive Officer, stated: "We are very pleased with the interest and positive market response for our private placement. Most of the capital will be used tactically to drill-test this exciting target, guided by a proven mine finder, Dave Mathewson. We are moving decisively on the drill program by today awarding the drill contract and for drilling to commence next month."

First Vanadium Corp. (FVANF), closed Friday's trading session at $0.2855, up 0.666408%, on 254,944 volume with 103 trades. The average volume for the last 3 months is 87,604 and the stock's 52-week low/high is $0.079999998/$0.3037.

chart

Flower One Holdings, Inc. (FLOOF)

Cash Crop Today, Investor Welcome, Midas Letter, Pot Network, Investor Place, Invest Tribune, Investor Ideas, Business Insider, NIC Investors, Stockwatch, WeedStreet420, Investors Hangout, Stockhouse, Investing News, New Cannabis Ventures, Pot Stock News, GlobeNewswire, MarketBeat, Street Insider, TradingView, Dividend Investor, InvestorsHub, Investors Observer, and Green Market Report reported beforehand on Flower One Holdings, Inc. (FLOOF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Flower One Holdings, Inc. is on the fast track to becoming the top cannabis cultivator, producer, and innovator in Nevada. The Company owns and operates a 25,000 square-foot cultivation and production facility in North Las Vegas, with nine grow rooms. Additionally, it owns the established NLV Organics consumer brand of cannabis products. OTCQX-listed, Flower One Holdings is based in Toronto, Ontario.

The Company is converting its 455,000 square-foot greenhouse and production facility for cultivating and processing high-quality cannabis at scale. The facility is the largest in the State of Nevada. Combined, the flagship greenhouse facility and production facility (upon being totally operational) and the North Las Vegas facility provide Flower One with 480,000 square feet of capacity for cultivation and processing, production, and high-volume packaging of dry flower, cannabis oils, concentrates, and infused products.

Flower One is completely licensed for medical marijuana cultivation and production, as well as recreational marijuana cultivation and production in Nevada. Currently, the Company holds licensing agreements with its Brand Partners - Flyte Concentrates, Rapid-Dose Therapeutics' Quick Strip, Old Pal, Palms, HUXTON, CannAmerica Brands, Grenco Science (G Pen), and The Medicine Cabinet.

In June, Flower One Holdings announced its latest partnership agreement with Lift Ticket Laboratories. By way of this partnership, Flower One Holdings will become the exclusive brand production partner for the Lift Tickets brand in Nevada, bringing all of Lift Tickets Laboratories' award-winning pre-roll products to Nevada. Furthermore, Lift Tickets Laboratories will be implementing a number of industry-leading proprietary pre-roll production methods and techniques at Flower One's flagship greenhouse facility to further enhance Flower One’s pre-roll manufacturing capabilities.

Last week, Flower One Holdings reported its financial and operating results for Q1 ended March 31, 2020. In addition, it provided a corporate update including preliminary financial and operational highlights subsequent to the quarter end.

Flower One delivered Revenue of $8.8 million. This represents sequential quarterly growth of 52 percent. The Company realized record monthly sales in March of $3.9 million. Moreover, Flower One maintained industry-leading cultivation performance levels with an average harvested cash cost of $0.49 per gram. It also received State of Nevada approval to launch three vape brands, including The Clear, Old Pal, and Heavy Hitters.

Flower One Holdings, Inc. (FLOOF), closed Friday's trading session at $0.344, off by 1.7143%, on 109,815 volume with 62 trades. The average volume for the last 3 months is 146,625 and the stock's 52-week low/high is $0.248799994/$2.07999992.

chart
n

Friendable, Inc. (FDBL)

NetworkNewsWire, Stockopedia, Stockwatch, Canadian Insider, last10k, Barchart, New Media Wire, Ceo.ca, Pink Investing, Journal Transcript, Insider Financial, Morningstar, GuruFocus, YCharts, Investing.com, InvestorsHub, Street Insider, TradeKing, hot Stocked, Global Banking and Finance, Speculating Stocks, Emerging Growth, CSI Market, Stock Market Watch, Seeking Alpha, Stockhouse, Whale Wisdom, Market Exclusive, EIN News, TipRanks, InvestorPoint, Investors Observer, CapitalEquity Review, OTC Markets, OTC.Watch, Stockaholics, Simply Wall St, Wallet Investor, The Hot Penny Stocks, Macroaxis, TradingView, GlobeNewswire, Nasdaq, and Accesswire reported earlier on Friendable, Inc. (FDBL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Friendable, Inc. is a mobile focused technology and marketing company listed on the OTC Markets. It connects and engages users via two distinctly branded applications. These are the Friendable and Fan Pass mobile applications. Fundamentally, the Company is a mobile technology business that develops, acquires, and invests in mobile applications with a social focus. The Company previously went by the name iHookup Social, Inc. It changed its name to Friendable, Inc. in September of 2015. Founded in 2007, Friendable is headquartered in Campbell, California.

Friendable first released its flagship product, Friendable, as a social application where users can create one-on-one or group-style meetups. In 2019, the Company released its new version of Friendable with a focus on dating and building subscription based revenue, starting with its existing and historical database of approximately 900,000 registered users.

Fan Pass is its newest app/brand. Fan Pass focuses on connecting Fans of their favorite celebrity or artist, to an exclusive VIP or Backstage experience. This is from their smart phone or other connected devices. Fan Pass enables an artist fan base to experience something they would otherwise never have the opportunity to afford or geographically attend. Furthermore, Friendable’s business model enables artists, musicians, and celebrities to leverage their social media followers and invite them to the show.

Yesterday, Friendable announced an iHeartRADIO interview featuring Friendable Chief Executive Officer, Mr. Robert A. Rositano, Jr., and also its new addition to the Atlanta performers line-up, artist Slugg Mania. Friendable is preparing for its Fan Pass Launch Event to take place today.

Mr. Rositano, Jr. said, “Exciting to be interviewed by iHeartRADIO this week, and to have an interviewer that is also an artist, which David Serero is, couldn’t have been a better fit. The interview was more than just an opportunity to share the Fan Pass vision, but one that allowed more feedback from someone like David, who could bring his objective perspective to what Fan Pass offers…”

Friendable, Inc. (FDBL), closed Friday's trading session at $0.0706, off by 16.8433%, on 331,270 volume with 53 trades. The average volume for the last 3 months is 58,494 and the stock's 52-week low/high is $0.017999999/$1.79999995.

chart

Hancock Jaffe Laboratories, Inc. (HJLI)

NetworkNewsWire, Streetwise Reports, Street Insider, MacroTrends, Research and Markets, TipRanks, InvestorsHub, Market Screener, Barchart, Investing.com, StockNews, Seeking Alpha, Accesswire, Stocktwits, DBT News, Nasdaq, TMXmoney, GuruFocus, Proactive Investors, Stockwatch, Stockhouse, Insider Monitor, GlobeNewswire, Stockopedia, Business Insider, Morningstar, and Simply Wall St reported earlier on Hancock Jaffe Laboratories, Inc. (HJLI), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Hancock Jaffe Laboratories, Inc. is a developer of medical devices that restore cardiac and vascular health. It specializes in developing and manufacturing bioprosthetic (tissue based) medical devices to establish improved standards of care for treating cardiac and vascular diseases. The design of each device is to allow vascular and cardiothoracic surgeons to achieve maximum effectiveness while considerably lessening the time and complexity of current procedures in concert with a dedication to efficient health care delivery.

Hancock Jaffe Laboratories is based in Irvine, California. Its shares trade on the NasdaqGS. The Company was founded in 1987. The present Management Team at Hancock Jaffe Laboratories has been associated with greater than 50 FDA (Food and Drug Administration) or CE marked medical devices. Currently, the Company has two lead product candidates - VenoValve® and CoreoGraft®.

VenoValve® is a porcine based valve intended to be surgically implanted in the deep venous system of the leg to treat reflux associated with Chronic Venous Insufficiency. CoreoGraft® is a bovine tissue based off the shelf conduit intended to be used for coronary artery bypass surgery.

At the beginning of June 2020, Hancock Jaffe Laboratories announced that it signed a non-binding Letter of Intent (LOI) to merge with Catheter Precision, Inc. Catheter Precision is a private medical device company centered on cardiovascular diseases. This includes heart arrythmias.

Catheter Precision has developed a software imaging system called VIVO™, an initial version of which is FDA cleared and CE marked. It produces a 3-D virtual image of the heart on a computer monitor for the purpose of accurately identifying and targeting the anatomical location of ventricular arrhythmias for catheter ablation therapy.

Yesterday, Hancock Jaffe Laboratories announced that Italian Hospital Asuncion in Paraguay has given the Company permission to proceed with the CoreoGraft first-in-human study. The study had been delayed because of constraints at the hospital caused by the COVID-19 pandemic. Patient selection for the three to five-person study will commence immediately.

CoreoGrafts will be implanted in patients requiring coronary artery bypass graft (CABG) surgeries. CoreoGraft patients will be monitored for a one-year period post CoreoGraft surgery, with interim results reported at 30, 90, 180, and 365 days post-surgery.

Hancock Jaffe Laboratories, Inc. (HJLI), closed Friday's trading session at $0.322, off by 9.0395%, on 4,838,045 volume with 5,624 trades. The average volume for the last 3 months is 1,693,525 and the stock's 52-week low/high is $0.211099997/$1.20000004.

chart

Millendo Therapeutics, Inc. (MLND)

BioPharmCatalyst, BioSpace, Growjo, InvestorsHub, YCharts, Finviz, Webull, Street Insider, TipRanks, Market Screener, Investors Observer, Business Wire, Simply Wall St, DBT News, Barchart, Stockhouse, Market Chameleon, Dividend.com, Equity Clock, GuruFocus, ETF.com, Morningstar, ChartMill, Investing.com, Invest Million, Trade Ideas, Stockopedia, TMXmoney, Seeking Alpha, Nasdaq, MarketWatch, MarketBeat, and Stocktwits reported beforehand on Millendo Therapeutics, Inc. (MLND), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

A biopharmaceutical enterprise, Millendo Therapeutics, Inc. mainly concentrates on developing novel treatments for endocrine diseases with significant unmet needs. At present, Millendo is advancing MLE-301 for the treatment of vasomotor symptoms associated with menopause. The Company believes in the ability to take advantage of scientific advances to develop novel compounds to treat complex conditions and advance clinical care. Millendo Therapeutics has its corporate headquarters in Ann Arbor, Michigan and an office in Lexington, Massachusetts. It also has a European office in Lyon, France. Millendo lists on the NasdaqGS.

Millendo Therapeutics’ MLE-301 is a reversible antagonist of the human neurokinin 3 recepter (NK3R) in development for the treatment of vasomotor symptoms (VMS) associated with menopause. It is a highly validated drug target with genetic, pharmacodynamic, as well as clinical data supporting a role in VMS. Vasomotor symptoms (VMS) are defined as hot flashes and night sweats in menopausal women. Studies to enable a first-in-human Phase 1 program with MLE-301 are underway.

MLE-301 directly targets the key neurons that are thought to control heat dissipation. Millendo Therapeutics believes the drug will act to antagonize the human NK3 receptor, a mechanism that is clinically validated to lessen the frequency and severity of VMS in postmenopausal women.

In June, Millendo Therapeutics announced that it has taken steps forward in its evaluation of strategic options to determine Millendo’s future direction. As part of these efforts, the Company has engaged SVB Leerink to support the strategic review process. Millendo finished Q1 2020 with $58.9 million in cash, cash equivalents, and restricted cash.

Julia C. Owens, President and Chief Executive Officer of Millendo Therapeutics, said, "Our Board of Directors and leadership team recognize the importance of conducting a comprehensive and strategic review. We are aligned in our focus on evaluating our pipeline and its potential, beginning with the advancement of MLE-301. Our objective is to come away from this process with an actionable plan that leverages our assets, capital and capabilities in a way that maximizes shareholder value."

Millendo Therapeutics, Inc. (MLND), closed Friday's trading session at $1.84, off by 7.5377%, on 1,231,494 volume with 3,929 trades. The average volume for the last 3 months is 1,596,814 and the stock's 52-week low/high is $1.25999999/$10.75.

chart

True Leaf Brands, Inc. (TRLFF)

Wall Street Reporter, Stock Day Media, FX Empire, Technical420, Central Charts, Investor Welcome, Wallet Investor, Stockwatch, GuruFocus, Barchart, OTC Markets, Proactive Investors, Wallmine, GlobeNewswire, Newsfilecorp, Stockhouse, Investor Ideas, Morningstar, Seeking Alpha, InvestorsHub, and TMXmoney reported earlier on True Leaf Brands, Inc. (TRLFF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

True Leaf Brands, Inc. is a wellness company for people and their pets. The Company lists on the OTC Markets and has two operating divisions. These are: True Leaf Cannabis, Inc.; and True Leaf Pet, Inc. True Leaf Brands has its corporate headquarters in Vernon, British Columbia.

The Company’s Founder, Darcy Bomford, has greater than 30 years of experience in the pet care industry. True Leaf Brands veterinary advisory team is chaired by Dr. Katherine Kramer, who is a champion of integrative care for pets.

The Company’s True Leaf Cannabis is a Licensed Producer (LP). True Leaf Cannabis owns True Leaf Campus, which is an 18,000 square foot facility situated on a 40-acre site zoned for the cultivation, processing, and sale of cannabis, and also general industrial use, in Lumby, British Columbia.

True Leaf Pet is a worldwide pet care company. True Leaf Pet offers plant-focused wellness products, which improve the quality of life for companion animals. True Leaf Pet says that it is guided by its corporate mission to "Return the Love" that was inspired by the unconditional love that pets give every day.

Ture Leaf Brands’ focus is natural support for pet companions. The Company’s family of products include Hemp Leaf CBD (cannabidiol) - Enhanced Calming and Hip + Joint Support; Hemp Seed - Calming, Hip + Joint, and Everyday Omega; and Oil of Oregano - Body + Oral Health Support. True Leaf Brands uses premium, naturally sourced ingredients.

The Company’s products include specially designed chews, oils, and also sticks. These are veterinarian-formulated. In addition, they contain human-grade, natural ingredients sourced from around the world. True Leaf’s unique formulations combine active ingredients with proven benefits that act together synergistically.

This week, True Leaf Brands provided an update on the status of the filing of its operating and financial results for the fiscal year ended March 31, 2020, accompanying management's discussion and analysis, and related Chief Executive Officer (CEO) and Chief Financial Officer (CFO) certifications (collectively Annual Filings), and the filing of its operating and financial results for Q1 ended June 30, 2020, accompanying management's discussion and analysis, and related CEO and CFO certifications (collectively Interim Filings). True Leaf estimates that it will file the Annual Filings on or before September 12, 2020, and the Interim Filings on or before October 13, 2020.

True Leaf Brands, Inc. (TRLFF), closed Friday's trading session at $0.0309, up 1.3115%, on 78,715 volume with 11 trades. The average volume for the last 3 months is 142,361 and the stock's 52-week low/high is $0.010099999/$0.25999999.

chart

WEED, Inc. (BUDZ)

Beat Penny Stocks, Green Leaf Pot Stocks, MicroSmallCap, TradeKing, Accesswire, Nasdaq, Investing.com, Market Screener, GlobeNewswire, Stockhouse, Insider Financial, CannabisMarketCap, Stock of the Week, Dividend Investor, GuruFocus, Barchart, Wallet Investor, Macroaxis, YCharts, Morningstar, OTC Markets, Seeking Alpha, Investors Observer, InvestorsHub, and Investor Place reported earlier on WEED, Inc. (BUDZ), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

WEED, Inc. is a multi-national, multi-faceted, vertically integrated cannabis company. It is structured as a holding company doing business by way of its divisions, wholly-owned subsidiaries, and strategically placed collaborative partners to attain and promote its worldwide agenda and brand. Established in 1999, WEED has its head office in Tucson, Arizona.

The Company previously went by the name United Mines, Inc. It changed its corporate name to WEED, Inc. in February of 2015. The Company’s shares trade on the OTC Markets Group’s OTCQB.

WEED’s subsidiaries include Sangre BioSciences; Weed Australia Ltd.; WEED Israel Cannabis Ltd.; The Hemp Institute of Arizona; and The Cannabis Institute of Australia. Sangre BioSciences is in the process of conducting a comprehensive Cannabis Genome Study to complete an international genomic classification of the cannabis plant genus.

WEED Australia Ltd.’s strategy is to use its proprietary research, medical patents, and clinical trials to create innovative medical products and services for the treatment of human and animal diseases. WEED Israel Cannabis Ltd. was founded to build and expand WEED, Inc.’s worldwide presence. In support of WEED Israel Cannabis Ltd., WEED, Inc. has entered into an exclusive license and assignment agreement with Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., Israel. This agreement is for five patents, technology, as well as knowledge regarding formulations for the administration and delivery of cannabinoid compounds.

The Hemp Institute of Arizona was created by WEED, Inc. to research and study the hemp plant, industrial and CBD (cannabidiol) strains, to create forward-looking cultivation techniques and to find new methods of extracting CBD compounds for use in medical applications. The Cannabis Institute of Australia was established by WEED Australia Ltd. as its non-profit division in March of 2018 with the aim of creating a Scientific Advisory Council to establish national protocols and procedures backed by scientific research.

WEED, Inc. (BUDZ), closed Friday's trading session at $0.292, up 6.1432%, on 76,638 volume with 64 trades. The average volume for the last 3 months is 144,082 and the stock's 52-week low/high is $0.170000001/$0.579999983.

chart

NaturalShrimp Incorporated (SHMP)

SeafoodSource, Stock Day Media, Micro Small Cap, Wall Street Analyzer, Transparent Traders, Micro Cap Daily, Stockwatch, Stockopedia, Perishable News, Emerging Growth, OTC Markets, OTC.Watch, Market Screener, Live Trading News, Stockhouse, Speculating Stocks, and Insider Financial reported earlier on NaturalShrimp Incorporated (SHMP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

An AquaCulture Company, NaturalShrimp Incorporated produces naturally-grown shrimp in the United States and internationally. It is a leader in the “Closed-System Shrimp Farming” industry. In 2016-17, the Company introduced its patented vibrio suppression technology that is potentially disruptive to the entire shrimp farming industry. NaturalShrimp’s European partner has built a production facility in Medina del Campo, Spain. Expansion plans include domestic and worldwide production facilities and distribution channels. NaturalShrimp is based in Addison, Texas. It has production facilities located near San Antonio, Texas. The Company lists on the OTC Markets’ OTCQB.

NaturalShrimp systems can be located anywhere in the world to produce gourmet-grade Pacific white shrimp. NaturalShrimp has developed a technology to produce fresh, gourmet-grade shrimp reliably and economically in an indoor, re-circulating, saltwater facility. Its eco-friendly, bio-secure design does not rely on ocean water. It recreates the natural ocean environment allowing for high-density production that can be replicated anywhere around the world.

The water systems used in production are electrified systems that help to control ammonia and bacteria, killing 99 percent of all bacteria. Shrimp are brought into the facility at 28 days old and are raised until maturity. This happens around 14 weeks of age.

Last week, NaturalShrimp announced that it has decided to rebuild in LaCoste, Texas. It has spent the last 10 weeks developing a detailed design of the next facility to serve as the model shrimp production facility for future expansion. The Company has now started the construction process. It has committed greater than $1.2M in orders for the Electrocoagulation (EC) equipment and the metal building structure.

The new 40,000 square foot shrimp production facility will be 6,000 square feet larger than the previous pilot plant. Furthermore, the plans include converting the existing 8,000 square foot greenhouse structure into a water treatment plant. This new, larger building will allow NaturalShrimp to increase production to more than 3,000 pounds per week when completed and fully stocked.

NaturalShrimp Incorporated (SHMP), closed Friday's trading session at $0.0925, up 39.9395%, on 47,943,017 volume with 2,960 trades. The average volume for the last 3 months is 6,994,738 and the stock's 52-week low/high is $0.023199999/$0.226999998.

chart

Golden Matrix Group, Inc. (GMGI)

Spotlight Growth, TipRanks, Stockflare, Stock Muse, Real Investment Advice, Simply Wall St, Stockopedia, GlobeNewswire, hot Stocked, Wallet Investor, InvestorsHub, Infront Analytics, Market Screener, 4-Traders, Nasdaq, Newswire, TraderNewsWire, OTC Markets, Stockhouse, TradingView, last10k, and Dividend Investor reported earlier on Golden Matrix Group, Inc. (GMGI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Golden Matrix Group, Inc. designs and develops social gaming platforms, systems and gaming content. A technology-driven company, it develops and owns online gaming IP (Intellectual Property) and builds configurable and scalable white-label social gaming platforms for its global customers, located mainly in the Asia Pacific region. The Company formerly went by the name Source Gold Corp. It changed its name to Golden Matrix Group, Inc. in March of 2016. Formed in 2008, Golden Matrix Group is headquartered in Las Vegas, Nevada.

Golden Matrix pioneers highly modular, configurable, and scalable social gaming platforms for its customers. This is to promote user acquisition, engagement, retention, and monetization. Its platform enhances clients’ ability to cater to different gaming scenarios. This includes, but is not limited to, transaction management and a range of loyalty/reward programs. Also, user engagement is optimized through Golden Matrix’s ability to accommodate free and cost to play games.

Concerning its Services, Golden Matrix has a completely operational platform. This platform delivers all features and services required to introduce a white label social gaming site. The Company offers Management services. It has a single suite of integrated applications to collect, store, manage and interpret real-time gaming data.

Services include incentivising users with credits, prizes, and rewards. As a result, this enhances user engagement and retention. Additionally, Golden Matrix provides access to first-rate games across in-demand gaming genres.

The Company also provides updates – the continual updating of gaming features and the addition of new games to reduce content sourcing. Golden Matrix’s sophisticated software automatically declines any gaming or redemption requests from within the USA, in strict compliance with present United States law.

Last week, Golden Matrix Group said its GM-X gaming platform has been licensed to 24 new gaming operator clients, with more than 40 additional such operators expected to license GM-X by the end of next month. At present, Golden Matrix has more than 310 gaming operator clients and more than two million registered end-users around the world.

Golden Matrix Group, Inc. (GMGI), closed Friday's trading session at $2.86, up 0.350877%, on 48,696 volume with 127 trades. The average volume for the last 3 months is 10,605,730 and the stock's 52-week low/high is $0.194999992/$4.00.

chart

Sunstock, Inc. (SSOK)

OTC Dynamics, Penny Stock Base, last10k, StockPulse, StockInvest.us, TipRanks, Whale Wisdom, Central Charts, Market Wire News, Street Insider, Capital Cube, EIN News, Market Exclusive, Market Screener, OTC Markets, 4-Traders, InvestorsHub and Investors Hangout reported earlier on Sunstock, Inc. (SSOK), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Sunstock, Inc. operates a coin store that buys and sells precious metal coins and also an asset-backed set of cryptocurrencies backed by gold, silver, and platinum. It operates one precious metals retail store under Mom’s Silver Shop in Sacramento, California. Sunstock pursues a “ground to coin” strategy. Thus, it secures and/or acquires mining assets and also rights to purchase mining production, and sells these metals mainly through retail channels through their own branded coins. Formed in 2012, Sunstock is headquartered in Sacramento, California.

Sunstock is moving ahead with “Triple 8”, precious metal asset-backed Crypto Tokens. The Company is redefining how the world conceptualizes and uses money with the pending launch of asset-backed cryptocurrencies, which are directly tied to the value of gold bullion. “Triple 8” provides a value proposition for investors and end-users of the token.

Sunstock’s plan is to become a pure gold play stock, with plans to own a complete Vertical Integration in the gold industry. Its intention is to acquire mineral rights and gold mining assets to complement its robust and growing gold distribution business. The Company anticipates acquisition prices in the $5,000,000 to $10,000,000 range. The mines it is considering are producing upwards of 60,000 ounces of gold annually.

Sunstock states that it is in talks to acquire or partnership with a number of assets that could potentially produce billions in revenue over 5-10 years. The Company is centered on projects that already own substantial amounts of unrefined – but already mined – gold ore.

Mr. Jason Chang is the Founder, Chairman, Chief Executive Officer and Investor Relations Officer of Sunstock, Inc. Mr. Chang has more than 20 years of hospitality management experience. He began his career in the hospitality industry in the family business operating several hotels throughout California.

This week, Sunstock announced that it added to its existing precious metals sales and distribution strategy by targeting acquisitions in the gold mining industry. At the same time, It is working with its partners and advisors on a strategy to uplist to the OTC Markets Group’s OTCQB.

Sunstock, Inc. (SSOK), closed Friday's trading session at $0.0026, up 26.8293%, on 110,950,217 volume with 646 trades. The average volume for the last 3 months is 7,981,481 and the stock's 52-week low/high is $0.00085/$0.023499999.

chart

Meso Numismatics, Inc. (MSSV)

RedChip, OTC Dynamics, TeleTrader, Last10k, TipRanks, Street Insider, Nasdaq, Simply Wall St, Investing.com, Financial Buzz, Dividend Investor, Otc.watch, InvestorsHub, MarketWatch, Stockwatch, Investors Hangout, GlobeNewswire, New Media Wire, Stockhouse, Wallet Investor, and TradingView reported earlier on Meso Numismatics, Inc. (MSSV), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Meso Numismatics, Inc. is a technology and numismatic company specializing in the Meso Region, including Central America and the Caribbean. It has become the primary hub for rare, exquisite, and valuable inventory from the Meso Region and worldwide. The Company was previously known as Pure Hospitality Solutions, Inc. It changed its name to Meso Numismatics, Inc. as a result of its merger with Meso Numismatics, Corp. in September of 2018. Meso Numismatics has its head office in Boca Raton, Florida.

Meso Numismatics is the only Company in the Central American-Caribbean region that is an on-the-ground registered dealer with the Numismatic Guaranty Company (NGC) and the Paper Money Guaranty (PMG). The Company has a selection of rare inventory, and also has a specialized App for banknote recognition, available on Google Play and the Apple App Store. Meso continues to partner with some of the largest auction houses internationally for the sale of the Company’s rarer inventory.

Meso Numismatics was established in September 2016 by a group of devoted coin collectors and currency seekers from the Mesoamerica area - from Mexico to Panama. The Company specializes in this area of the region. Moreover, Meso also has inventory and clients from all over the world. Numismatics is the study or collection of currency. This includes coins, tokens, paper money, as well as related objects.

In September, Meso Numismatics announced that it has preliminarily completed the due diligence phase of the Green Pay acquisition and is now set to proceed with an audit of Green Pay to be performed by the Company’s independent registered accounting firm. According to Management, Meso’s counsel will soon begin preparing the definitive purchase agreement for the Green Pay acquisition.

Afterward, the expectation is that Meso Numismatics will issue shares of its Preferred Stock as an initial payment for the acquisition. Following that, its U.S. independent registered accounting firm will start to audit Green Pay’s financials, preparing them to be included in Meso’s SEC filings at some later date.

At present, Green Pay hosts 110 independent stores located around Central America; processes around $2.5M in monthly transactions among all of its users; and executes roughly 500,000 transactions per month. Green Pay also has approximately 400,000 monthly active users; and has about 650,000 registered credit cards representing multiple payment institutions around Central America.

Meso Numismatics, Inc. (MSSV), closed Friday's trading session at $0.015, up 54.6392%, on 8,000 volume with 1 trade. The average volume for the last 3 months is 38,760 and the stock's 52-week low/high is $0.007199999/$0.148000001.

chart

Prism Technologies Group, Inc. (PRZM)

Zacks, Wall Street Journal, TradingView, MarketWatch, and InvestorsHub reported on Prism Technologies Group, Inc. (PRZM), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Prism Technologies Group, Inc. is an intellectual property (IP) licensing and technology research & development  (R&D)  company. The Company, by way of its wholly-owned subsidiaries, owns a patent portfolio consisting of nine patent families incorporating 61 issued and six pending patents in the Computer & Network Security, Semiconductors, and Medical Technology arena.

  Established in 1995, Prism Technologies Group is the parent company of Prism Technologies, LLC, which is a Nebraska Limited Liability Company (LLC) based in Omaha, Nebraska. Prism Technologies Group has its corporate office in Folsom, California.

The Company previously went by the name Internet Patents Corporation. It changed its name to Prism Technologies Group, Inc. in September of 2015. The Company lists on the OTC Markets Group’s OTCQB.

  Prism Technologies Group licenses and enforces a portfolio of patents relating to its technologies. It continues to develop and patent new technologies.

The Company’s dedication is to continuing R&D efforts in a number of fields. Its mission is to continue to develop and invent new technologies in computer and network security, wearable computing, transaction processing,  and healthcare to speed up time to market opportunities for its clients.

Prism Technologies Group’s Executive Team includes Mr. Hussein A. Enan - Chairman, Chief Executive Officer; and Mr. Greg Duman - President, Prism Technologies, LLC and member of Prism Group's Board of Directors. Mr. Duman chairs the Audit Committee.

Prism Technologies Group announced in October of 2017 that it entered into an Asset Purchase Agreement with Amorphous Technologies International (ATI). ATI is a leader in the development of innovative amorphous alloy solutions based on proprietary materials technology. Its solutions deliver value through removing the limits of existing materials technology, which result in high costs throughout the lifecycle of a product.

The Agreement is to acquire certain intellectual property (IP) assets related to unique uses for amorphous metals.  After the close of the transaction, Prism will commercialize the acquired IP assets to create new amorphous metal technology offerings for the consumer electronics, automotive, industrial, and other business sectors.

Prism Technologies Group, Inc. (PRZM), closed Friday's trading session at $0.0449, up 124.50%, on 550 volume with 2 trades. The average volume for the last 3 months is 966 and the stock's 52-week low/high is $0.014999999/$0.05186.

chart

Tautachrome, Inc. (TTCM)

MarketWatch and InvestorsHub reported on Tautachrome, Inc. (TTCM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tautachrome, Inc. is an emerging growth enterprise in the developing digital imagery technology sector. It is a developer of software applications for trustable and engageable digital pictures and videos. The Company’s chief priority is developing its branded KlickZie platform. An Internet technology development business, Tautachrome is headquartered in Oro Valley, Arizona and has operations in the United States and Australia.

The KlickZie platform will turn smartphones into trusted imagers. This means the pictures and videos they capture can be verified as original, untampered,  and un-photoshopped. Additionally, the KlickZie platform creates imagery that is interactive and engageable.

The KlickZie platform will serve as the world’s first imagery-based social website network. Through clicking or tapping on a KlickZie'd image, users can communicate with the image's author or others presently looking at the image, in an engaging way.

Basically,  KlickZie is an image verification service for smartphones. It brings trust back to digital imagery. In addition, KlickZie turns the smartphone into a reliable image source. Smartphone users download KlickZie’s free software to take their pictures and videos.

KlickZie pictures and videos are invisibly marked, stored in the KlickZie cloud, and guaranteed free from manipulation. The cloud will certify the authenticity of any KlickZie picture or video.

Tautachrome also has pioneering patents pending. These include Talk-to-the-Picture social networking and the abovementioned trustable imagery-based interaction.

Tautachrome is establishing a development team of providers to develop a blockchain based cryptocurrency ecosystem with a cryptotoken designated “KLK”. It will be the currency of the KlickZie community internationally.

This will permit KlickZie users to monetize their pictures and videos. As a result, it will enable the buying, selling, and licensing of KlickZie pictures and videos everywhere.

Recently, Tautachrome announced that it hired the Pryor Cashman law firm in New York to lead its work to register its KLK cryptotoken sale with the Securities and Exchange Commission (SEC). Mr. Ali Panjwani with support from his colleagues Mr. Jeff Alberts and Mr. Mike Campoli is leading the Pryor Cashman work team.

This team has considerable cryptotoken knowledge. In addition, it has significant experience with SEC registration. This includes past employment with the SEC in this area.

Tautachrome Chief Executive Officer, Dr. Jon N Leonard, said, “I have directed the Pryor Cashman team to work with the SEC’s crypto currency task force to ensure that our vision for a KLK cryptotoken-based ecosystem, able to monetize the world’s smartphone imagery becomes a reality, and that it is fully compliant with SEC regulations. We appear to be breaking new ground in this work. But I believe that the social and economic potential of this effort is so great, that every effort is justified.”

Tautachrome, Inc. (TTCM), closed Friday's trading session at $0.0102, up 25.9259%, on 74,785,661 volume with 1,229 trades. The average volume for the last 3 months is 20,310,638 and the stock's 52-week low/high is $0.0019/$0.0259.

chart

Mitesco, Inc. (MITI)

Real Pennies, MarketWatch, InvestorsHub, Marketwired, Stockhouse, and OTC Markets reported  on Mitesco, Inc.  (MITI), and  today we are reporting on  the Company,  here at the QualityStocks Daily Newsletter.

True Nature Holding, Inc., now known as Mitesco, Inc. (OTCQB:TNTY, OTCQB:MITI) (the “Company” or “True Nature” or “Mitesco”) has a business plan consisting of a roll-up strategy in the compounding pharmacy industry. The plan contemplates  manifold  acquisitions of businesses that  have conventionally operated locally, but that have specialty formulations  that  may have a larger market.  The Company is  targeting the acquisition of pharmacies that serve the human, and in some  cases, pet markets. True Nature Holding  has its corporate office in Atlanta, Georgia.

True Nature Holding’s focus is on the consolidation of the compound pharmacy industry.  Its plan is to acquire a series of businesses that specialize in compounding pharmacy activities,  primarily direct to consumers, and to doctors and veterinary professionals.  Pharmaceutical compounding is performed  in compounding pharmacies. It is the creation of a specific pharmaceutical product to fit the exclusive need of a patient.  

The Company  has acquired 100 percent of the membership interests of Newco4pharmacy, LLC. Newco4pharmacy is a development stage business targeted  at establishing a network of compounding pharmacies. 

  Mitesco is creating a  blend  of human  and veterinary  businesses,  and  a balance of cash oriented operations, and more  usual  insurance based operations.  The Company expects to create three operating subsidiaries to hold its planned acquisitions, while maintaining its present holding company structure for the publicly held entity.  The expectation is that  all the new subsidiaries will be wholly-owned, single member LLC's, controlled and managed by the public company. 

   Mitesco’s  intention is to  establish  a joint venture (JV) for-profit subsidiary; True Nature Community Health, Inc.  This will be owned by the public company, and  a newly formed not-for-profit entity; The True Nature Community Health Foundation. It is launching this new initiative targeted  at supporting the need for lower cost pharmaceuticals within the medically underserved small town and rural marketplaces.

  Mitesco is in the process of acquiring  the  newly formed subsidiary; True Nature Community Health, Inc. (Community Health Subsidiary). It will have an 80 percent  ownership in the Community Health Subsidiary. The remaining 20 percent  ownership will be held by not-for-profit organizations.

Last month, True Nature Holding released an update to its shareholders on its strategy. This includes potential acquisitions, financing prospects, and its position concerning plans to participate in the Cryptocurrency and Blockchain space.

Regarding acquisitions, Dr. Jordan Balencic, Chairman, and interim Chief Executive Officer, said, "First, in alignment with our current business model, we have three near-term acquisition prospects at this time. The smallest is an asset acquisition involving the operating assets of a compounding pharmacy operation near West Palm Beach, Florida… Secondly, we have had some discussions with a group of investors who hold interests in a set of clinics, diagnostic facilities, and pharmacies, generally in Florida, mostly in the Dade and Broward county markets.”

Dr. Balencic continued, "We have continued conversations with other pharmacy operators with whom we have had long-term relationships, and subject to terms and financing, could move on those in early 2018 as well as the others previously mentioned."

Mitesco, Inc. (MITI), closed Friday's trading session at $0.056, off by 13.8462%, on 820,721 volume with 55 trades. The average volume for the last 3 months is 1,489,650 and the stock's 52-week low/high is $0.016/$0.083499997.

chart

The QualityStocks Company Corner

Cybin Corp.

The QualityStocks Daily Newsletter would like to spotlight Cybin Corp..

As big pharma has failed to bring groundbreaking drug innovations into the mental health space, new data increasingly shows that psychedelics may close this gap, creating an entirely new market of safe and effective psychedelics medicines (http://ibn.fm/M6gla). Cybin Corp., a leading Canada-based, life-sciences company, is focused on developing pharmaceutical-grade psychedelic products and appears ideally positioned to make the most of this groundbreaking research.

Cybin Corp. is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.


Recent News

chart

DarioHealth Corp. (NASDAQ: DRIO)

The QualityStocks Daily Newsletter would like to spotlight DarioHealth Corp. (DRIO).

Digital therapeutics innovator DarioHealth (NASDAQ: DRIO) is building bridges that will help it cross over the Atlantic Ocean and begin serving Europeans with the company’s health monitoring solution. The company announced July 20 that it has entered into a strategic partnership with Williams Medical to make the DarioHealth Remote Patient Monitoring (“RPM”) digital therapeutics platform available to healthcare professionals across the United Kingdom and Ireland (http://ibn.fm/ikMWo). Also today, the company was featured in a publication from BioMedNewsBreaks, examining how DRIO was recently featured in a Data Bridge Market Research report. The piece highlighted DarioHealth’s advancements in digital diabetes management, a rapidly growing market expected to become the “next best thing” in the wake of the current coronavirus pandemic that has made it more difficult for patients to receive treatment. To view the full article, visit: http://ibn.fm/8xeWV.

New York and Israel-based DarioHealth Corp. (NASDAQ: DRIO) leads global digital therapeutics (DTx) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:

  • AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
  • Personalized user experience at scale to make behavior change the path of least resistance.

Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.

Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (RPM), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.

Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.

Company Strategy

Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).

Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.

Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.

Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.

The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.

The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.

Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.

Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.

Financial Highlights

The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.

Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (ARPU), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.

Value to Consumers and Businesses

Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.

Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.

Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.

Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.

Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.

Recent Studies

The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.

Remote Patient Monitoring (RPM) Agreements

The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.

This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.

Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters

In an effort to preserve personal protective equipment (PPE) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.

Awards and Recognition

DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”

‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.

DarioHealth Corp. (DRIO), closed Friday's trading session at $8.00, up 6.5246%, on 82,573 volume with 365 trades. The average volume for the last 3 months is 77,204 and the stock's 52-week low/high is $3.01999998/$13.1260004.

Recent News

chart

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology (NASDAQ: POAI) was featured today in a publication from BioMedWire, examining how internet use in the medical industry has tremendously grown over the past years. The continual propagation of mobile medical devices and the amount of data in hospitals are trends medical device manufacturers should keep in mind. Also, tracking cyber-security trends should be the main aim of device manufacturers due to an increased number of cyber-attacks on medical devices. Since lives are at stake, the FDA has stepped in to guide manufacturers to ensure the safety of medical devices in the global internet world. It has called for the protection of these devices as hackers may hack them for malicious purposes.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Friday's trading session at $1.67, up 1.8293%, on 2,101,608 volume with 4,125 trades. The average volume for the last 3 months is 1,147,430 and the stock's 52-week low/high is $1.25/$7.0999999.

Recent News

chart

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (OTCQB: SHRG), a publicly traded company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct-selling sector and other industries, announced its FY 2020 revenue numbers, including an increase of more than 50% over last year’s numbers (http://nnw.fm/PEGN4). SHRG announced the figures in conjunction with filing its annual SEC 10-K report.

Sharing Services Global Corporation (SHRG), formerly Sharing Services Inc., is a diversified company dedicated to maximizing shareholder value, operating through two primary subsidiaries: Elepreneurs Holdings, a direct-selling company, and Elevacity Holdings, a products company. Headquartered in Plano, Texas, SHRG markets and distributes Elevate-branded health and wellness products through an independent sales force of distributors called Elepreneurs.

Proprietary Products

SHRG’s current exclusive Elevate product offerings are marketed under the Elevacity brand, so named to signify the company’s commitment to elevating lives.

The Elevate health and wellness product line consists of nutraceutical products that SHRG refers to as D.O.S.E., which stands for dopamine, oxytocin, serotonin and endorphins – all of which are key hormones proven to promote happiness and well-being.

Elevacity brand products are carefully formulated, chosen and designed to support a single objective: elevate the happiness and well-being of the consumer.

Global Network of Elepreneurs

Elevacity products are shared and sold by a growing international network of home-based entrepreneurs, called Elepreneurs, operated by Elepreneurs Holdings. This SHRG subsidiary provides basic and advanced programs for both new and experienced entrepreneurs who are focusing on their direct-sales careers.

SHRG’s high-performing independent sales force follows the company’s Blue Ocean selling strategy, an approach that encourages individuals to seek new markets, lead, and to “stop competing and start creating.” The Blue Ocean strategy is based on the book, “Blue Ocean Strategy,” written by Professor Renée Mauborgne, who notes that “the lesson here is that the best defense is offense, and the best offense… is to make a blue ocean shift and create your own blue ocean.”

Following this selling strategy, SHRG’s Elepreneurs are taught that, rather than competing directly in a competitive, direct-selling market, they should focus on making competitors irrelevant and succeeding in an uncontested marketplace.

In addition, SHRG’s Elepreneurs use the interactive, video-based VERB sales-marketing platform developed by Verb Technology Company Inc. The app utilizes proprietary interactive video data collection and analysis technology and provides next-generation customer relationship management, lead generation, and video marketing software applications.

Continued Momentum as Industry Leader

These selling strategies have resulted in sharp and consistent revenue gains. In the company’s 10-Q filed with the SEC for the three months ended Oct. 31, 2019, SHRG reported sales of $38.8 million for fiscal Q2 2019, an increase of 116% over sales of $17.9 million reported for the comparable quarter of 2018. Consolidated gross profit jumped by $16.2 million to $27.4 million for the same period compared to Q2 2018.

SHRG’s consolidated operating earnings were $3.9 million in the fiscal quarter ended Oct. 31, 2019, compared to $866,802 for the comparable period the prior year. Consolidated gross margin also grew 70.9% for the three months ended Oct. 31, 2019, compared to 62.2% the prior year.

These numbers are continuing a trend established over the past two years. In fiscal Q1 2019, SHRG achieved revenues of $35.4 million, more than double that of the comparable period in 2018. Even earlier, the company reported sales of $85.9 million for fiscal year ended April 30, 2019. This represents a nine-fold increase, or $77.5 million jump, over the company’s revenues of $8.4 million the prior year.

These numbers bring SHRG’s sales revenues since December 2017 — when the company’s Elevate product line was released — to an impressive cumulative total of $169 million.

Preparing for Success

SHRG is well prepared to continue and accommodate for this growth. The company recently expanded its corporate footprint by moving to a 10,000-square-foot facility in Plano, Texas, that offers ample room to expand as the company grows and flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

In addition, the company has a seasoned, expert leadership team in place, led by John “JT” Thatch. Thatch was appointed president and CEO of SHRG in March 2018, bringing to the company his expertise obtained from successfully starting, owning and operating several businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist SHRG as the company aims to expand and increase revenues.

Contact
469.304.9400 x 201
Info@SHRGinc.com
http://www.SHRGinc.com

Sharing Services Global Corporation (SHRG), closed Friday's trading session at $0.212, up 19.774%, on 616,284 volume with 127 trades. The average volume for the last 3 months is 126,333 and the stock's 52-week low/high is $0.0215/$0.249799996.

Recent News

chart

Kingman Minerals Ltd. (TSXV: KGS)

The QualityStocks Daily Newsletter would like to spotlight Kingman Minerals Ltd. (TSXV: KGS).

Kingman Minerals (TSX.V: KGS), a Canada-based company engaged in the acquisition, exploration and development of gold and silver properties in North America, is positioned for opportunity in an uncertain time characterized by record unemployment, stock market volatility and trillion-dollar stimulus packages. To view the full article, visit: http://nnw.fm/eUwWX

Kingman Minerals Ltd. (TSXV: KGS), formerly Astorius Resources Ltd., is engaged in the acquisition, exploration and development of gold and silver properties in North America. The Canada-based company is focused on sourcing and developing high-quality properties in favorable mining locations to advance its diverse portfolio of low-cost, lifelong assets.

Kingman Mine

The Company maintains the following projects:

The Mohave Project: Located in the Music Mountains in Mohave County, Arizona. Approximately 35 miles from the town of Kingman, the property consists of 20 lode claims, including the historic Rosebud Mine. The Company has entered into an option agreement to earn 100% over four years. According to historic mappings of the mine, probable ore is 15,560 tons. Possible (inferred) ore is comprised of 176,000 tons, and additional possible (inferred) ore totals slightly over 1,100,000 tons. The total contained gold ounces for all categories is estimated at 664,000 ounces, and contained silver is estimated at 2,600,000 ounces. The Company has recently completed two underground reconnaissance and sampling programs and is in the process of verifying previous resource estimates.

 

The Cadillac East Property: Located approximately 55 kilometers east of Val d’Or, a hub for exploration and mining activities in the Canadian province of Quebec. The Company acquired a 100% interest in the property from an arm’s length vendor. Cadillac East Property consists of 12 claims, and the Company has an option agreement to earn 100% over three years. Having been the subject of numerous geophysical and geological surveys, the Cadillac East Property has been explored and surveyed by numerous companies as well as by the Quebec government. Exploration work done in 2017 by Exploration Facilitation Unlimited Inc. revealed multiple potential targets for future investigation, as results from the soil program identified value in gold, silver, copper, zinc and nickel.

Kingman Minerals is focused on enhancing shareholder value as it continues exploring potential assets and acquiring strategic gold targets. The company recently commissioned mining consulting services company Burgex Mining Consultants Inc. to complete two underground gold exploration programs in the historic Rosebud Mine. Burgex specializes in mineral exploration, mining claim staking, landman services, mining consulting, and the access and documentation of abandoned mine sites throughout the western United States and the world. Burgex’s founders have been active in the industry since 2007 and have identified, secured and consulted on hundreds of thousands of acres of mineral properties spanning a wide range of mineral commodities with billions of dollars’ worth of resources and reserves. The Burgex team has been featured in Forbes Magazine as well as on the Discovery Channel and other outlets. Burgex is at the vanguard of industry advancements in safely accessing difficult vertical abandoned mine workings and continues to pioneer new mineral exploration methods with strategic partners throughout the United States and the world.

Gold’s Predicted Rise

The value of gold is currently on an upward climb due to COVID-19’s upending of the global economy, causing governments to expand their balance sheets. In 2019, as a result of the housing and financial crisis, gold saw its best performance since 2010increasing as much as 20% and hitting a top price of $1,549 per ounce in September of that year. Analysts predict its price will continue to climb due to strong buying by central banks, a weakening of the U.S. dollar, and increasing political tensions. A recent Wolfe Research report predicted gold would hit an all-time high, referencing an ounce of gold that commanded a $1,515 asking price. As the value of the U.S. dollar weakens, the demand for gold is inversely rising. Known as a safe-haven asset, gold tends to see increased levels of demand during times of consumer fear or recession.

Management

Sandy MacDougall – Chairman and Director
An economics graduate from the University of British Columbia, Sandy MacDougall brings 30+ years of experience in the investment banking and finance industry to KGS. He was instrumental in the acquisition, development and production of gold at the Alto el Toro mine near Ibaguel, Columbia. As a former investment advisor at Canaccord Capital Corp., MacDougall was a key player in multiple significant financings in Canada as well as abroad, working with a wide range of companies. His experience has afforded him critical exposure to precious and base metal projects throughout North and South America, and he has served as chairman of the board since 2016.

Arthur Brown – President and Director
With 36 years of business experience and service to the boards of eight other companies in sectors ranging from technology to oil, gas and mineral exploration, Arthur Brown adds substantial knowledge in corporate structure and development as well as financings and venture capital to the KGS team.

Cyrus Driver – Independent Director
Cyrus Driver was a founding partner in the firm of Driver Anderson from its inception in 1982 and is a chartered accountant as well as a retired partner in the firm of Davidson and Company LLP. Aside from providing general public accounting services to a diverse range of clients, his specialty is servicing TSX Venture-listed companies and members of the brokerage community. With expert knowledge of the securities industry and its regulations, Driver lends valuable advice to his clients regarding finance, taxation and other accounting-related matters. He currently serves as director and chief financial officer of several TSX-V-listed companies.

Dr. Peter Born – Director and Technical Specialist
A professional geologist registered with the Association of Professional Geoscientists of Ontario and a fellow of the Geological Association of Canada, Dr. Peter Born brings 30+ years of experience in exploration and mining to the company. With prior roles as a senior geologist with Western Mining Corporation, he is currently working with RPS Energy Canada Ltd. on natural gas plays related to high-temperature dolomites and sedimentary zinc deposits (MVT) within the Appalachian Basin in the United States. Dr. Born holds a Ph.D. in earth sciences and has expertise in Precambrian sedimentary geology, basin analysis, sedimentology, stratigraphy and sedimentary ore deposits.

Kingman Minerals Ltd. (TSXV: KGS), closed Friday's trading session at $0.08, even for the day, on 1.,000 volume with 1 trade. The average volume for the last 3 months is 103,910 and the stock's 52-week low/high is $0.07/$0.22.

Recent News

chart

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the additive manufacturing industry, on Thursday reported financial and operational results for the second quarter ended June 30, 2020. Among other highlights, the company reported revenue of $0.2 million for the quarter, marking a significant increase compared to revenues of $34,000 for the second quarter of 2019. To view the full press release, visit http://nnw.fm/SOh6I

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Friday's trading session at $2.52, off by 1.1765%, on 190,318 volume with 698 trades. The average volume for the last 3 months is 561,684 and the stock's 52-week low/high is $1.97000002/$17.00.

Recent News

chart

SRAX Inc. (NASDAQ: SRAX)

The QualityStocks Daily Newsletter would like to spotlight SRAX Inc. (NASDAQ: SRAX).

Increasing privacy concerns over the use of personal data have played a large part in driving users away from many popular social media platforms that include the loss of over 15 million users by Facebook in less than two years (http://nnw.fm/AiOIF). Accordingly, nearly 90 countries and independent territories throughout the world have now adopted comprehensive data protection laws that aim to protect the public from marketers that obtain and sell data without their explicit permission (http://nnw.fm/luFXd). SRAX Inc. (NASDAQ: SRAX), a digital marketing and consumer data management technology company, evades this problem through its transparent BIGtoken network that compensates millions of users when they opt in to sell access to their data while simultaneously creating valuable data sets that marketers can access for a fee. Also today, NetworkNewsWire released a report on the company detailing how SRAX is leveraging a trending demand for increased communication and transparency in an era of big information. SRAX delivers platform solutions to owners and seekers in this big data age with tools to help both consumers and brands across various industries. To view the full article, visit: http://nnw.fm/0xwCW

SRAX Inc.'s (NASDAQ: SRAX) is a digital marketing and consumer data management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and their characteristics across marketing channels.

Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby providing everyone in the internet ecosystem choice, transparency and compensation.

SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform.

SRAX Verticals

  • SRAX Core: SRAX Core is a custom digital media management platform that enables brands and agencies to surpass the challenges of omnichannel marketing campaigns. It offers one comprehensive dashboard to manage digital media campaigns, inventory and reporting.
  • SRAX Social: SRAX Social is a free social media management tool that makes it easy for brands, agencies and individuals to grow their digital presence. It offers free and unlimited users, Facebook auto boosting, and a custom analytics dashboard. Its managed services team can also build and execute marketing plans for your unique specific needs.
  • SRAX IR: SRAX IR unlocks stock buyers’ behaviors and trends for issuers of publicly traded companies. The platform provides insights on shareholders and market makers, investor relations management, shareholder outreach tools and data-driven marketing.
  • SRAX Auto: SRAX Auto unlocks auto intenders’ data to create measurable connected experiences on the road to purchase. It offers proprietary auto intender profiles, multi touchpoint communication and custom location-based ads.
  • SRAX Shopper: SRAX Shopper delivers a cross channel, premium digital experience at scale to high value shopper audiences. It offers proprietary shopper profiles, cost per click pricing, and custom text and add to cart ad units.
  • SRAX Lux: Launched in June 2019, the SRAX Lux platform targets and reaches luxury consumers at luxury retail stores, high-end art, music, film, fashion and sports events, across all consumer devices.

BIGtoken

BIGtoken, available for download on the App Store and Google Play, revolutionizes data collection. BIGtoken is a platform that creates a secure and transparent environment for consumers to own and earn from their data. To date, there are 15.9 million BIGtoken registered users worldwide.

The optimization and monetization of data is a multibillion-dollar business. Worldwide spending on big data and business analytics solutions reached $166 billion in 2018 and is projected to surge to $260 billion by 2022. BIGtoken’s consumer vision is committed to delivering choice, transparency and compensation to the individual.

Through BIGtoken, consumers earn rewards when they opt into sharing their data and when that data is purchased. Consumers decide what data is shared, who can buy it and how it’s used, and advertisers reach real, responsive audiences. The benefit of this is two-fold: consumers know how their data is used and advertisers gain verified consumer data for targeting.

Users of the BIGtoken app can officially be paid in cash or gift cards in exchange for giving brands access to their anonymized data, answering questions, checking into locations, recruiting new members, and more. Users can deposit their earnings directly into PayPal accounts or be paid through gift cards from favorite retailers such as Walmart.

SRAX has also partnered with several high-profile, nonprofit associations to provide BIGtoken users the ability to donate their earnings. Partnerships include the American Heart Association, dedicated to fighting heart disease and stroke; HealthCorps, which helps high school students make better choices about health and physical fitness; and the ALS Association, which recently launched its Challenge Me campaign.

International Expansion

BIGtoken is formally launching into several international markets and partnering to foster local support. SRAX recently signed a joint venture with the Yash Birla Group to launch BIGtoken in India. Based in Mumbai, the Yash Birla Group, one of India’s largest conglomerates, has diversified interests in consumer and industrial products.

The partnership will bring BIGtoken’s platform to India, which has a digital population of 627 million. The India digital advertising market is $3.6 billion and is set to grow at a compound annual growth rate of 32%, making it one of the largest growing digital ad markets in the world.

SRAX Mexico is led by Moe Avitia, who has more than 18 years of experience in business development and building high-tech teams. SRAX Mexico includes a team of 90 employees, including 70 engineers.

BIGtoken Europe is currently evaluating data centers in individual countries for privacy laws.

Leadership

Christopher Miglino is CEO and founder of SRAX. He has spent the past 20 years working in the digital advertising space and has successfully launched and sold two internet companies. Both of these companies were sold to publicly traded companies on the NASDAQ. He has a detailed understanding of how technology interacts with brands.

Kristoffer Nelson is COO of SRAX and a founding member of BIGtoken. With over 15 years of technology and creative business experience, Nelson has been a guest speaker for Loyola Marymount University among other academic institutions, the National Association of Broadcasters, the IAB and numerous other professional and media organizations.

SRAX Inc. (NASDAQ: SRAX), closed Friday's trading session at $2.42, off by 5.4688%, on 22,294 volume with 114 trades. The average volume for the last 3 months is 69,285 and the stock's 52-week low/high is $1.04999995/$4.30439996.

Recent News

chart

Champignon Brands Inc. (FWB: 496) (CSE: SHRM) (OTC: SHRMF)

The QualityStocks Daily Newsletter would like to spotlight Champignon Brands Inc. (CSE: SHRM).

Champignon Brands Inc. (“Champignon” or the “Company”) (CSE: SHRM) (FWB: 496) (OTCQB: SHRMF) is pleased to announce it has filed business acquisition reports in connection with its previous acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. Copies of the reports are available for review under the Company’s profile on SEDAR (www.sedar.com). The filings are part of Champignon’s commitment to work with the British Columbia Securities Commission to complete its previously announced disclosure review in a timely fashion. The review relates to the Company’s disclosure obligations since it became a reporting issuer on February 6, 2020 and includes a review of the disclosure surrounding recent acquisitions completed by the Company.

Champignon Brands Inc. (FWB: 496) (CSE: SHRM) (OTC: SHRMF) is a research-driven company specializing in the formulation and distribution of a suite of artisanal mushroom health supplements. Dedicated to revolutionizing conventional organic teas, coffees and other consumables with the infusion of a proprietary blend of artisanal mushrooms, Champignon’s expanding portfolio is crafted with the health-conscious consumer in mind.

Headquartered in Vancouver, British Columbia, Champignon’s team aims to promote the health and wellness benefits of functional mushrooms, which are used in a wide variety of health care and pharmaceutical products.

Brands

Champignon’s mushroom-derived consumer packaged goods (CPGs) portfolio includes its flagship brand, Vitality Superteas. Each carefully curated Vitality Supertea formulation was developed with the intent of helping individuals enhance and enrich their wellbeing one cup of mushroom-infused tea at a time.

Also in the portfolio are Nourish Force Supertea, a blend of Reishi Ryobus Tea Mix; Mighty Recharge Supertea, created with Lions Mane Tropical Green Ginseng Tea Mix; and Brain Enhance Supertea, a blend of Cordycep Hibiscus and Berries Tea Mix – all of which are formulated with organic ingredients and chosen for their ability to provide unique health and performance benefits.

Champignon’s flagship e-commerce store, VitalitySuperTeas.com, takes advantage of the burgeoning craft mushroom vertical space with a selection of mushroom-infused teas and accessories.

Functional Mushroom Market

Demand for consumer products infused with the nutritional and bioactive benefits of mushrooms is fueling a global market projected to reach $34.3 billion by 2024, growing at a compound annual growth rate of 8.04% from 2019-2024 (ResearchandMarkets), with Europe seen as the fastest growth leader.

According to the market study, in highest demand are products infused with Reishi – a traditional Chinese medicine also known as the “Elixer of Life” and “Mushroom of Immortality – Lions Mane and Cordyceps, followed by other types of medicinal mushrooms.

Advances in Legalization

Legalization of psychedelics for use in medicine is gaining momentum across the United States. Denver, Colorado, and Oakland and Santa Cruz, California, have decriminalized the use of psilocybin, the psychedelic molecule found in various mushrooms, while movements for legalization are gaining ground in Oregon and Iowa, among others. Decriminalize California recently teamed up with the Beckley Foundation to replicate Oakland’s success of decriminalization throughout the state of California.

An increasing number of researchers are turning their attention toward the study of psilocybin as a means to treat otherwise untreatable illnesses. The molecule’s ability to provide landmark treatment options for depression, post-traumatic stress disorder (PTSD), migraines and addiction is gaining widespread acceptance among medical professionals, unicorn investors and accredited institutions.

Potential Applications

Historical data and new scientific studies suggest therapeutic benefits of psychedelics in many areas, including drug addiction, alcoholism, depression, migraines, smoking cessation and post-traumatic stress disorder (PTSD).

The market potential in these areas are significant. To reference just one of the above conditions, the mental health arena has been frequently neglected over the last 30 years, though new research is beginning to further reinforce that psychedelic compounds have the potential to produce more effective treatments than what is currently available.

According to the World Health Organization, 25% of the world’s populous will be afflicted by mental health and/or neurological disorders. Presently, approximately 450 million people currently suffer from such conditions, placing mental disorders among the leading causes of ill-health, productive loss and disability worldwide.

Additionally, PTSD affects approximately 2.2% of the U.S. population; 7.7 million people will have PTSD at some point in their lives. Recent published studies have demonstrated the safety and efficacy of certain psychedelics when administered in a medically supervised and monitored approach.
A renaissance in alternative medicines is emerging, and Champignon has set in motion its strategy to become a key player.

2020 Stealth IP Strategy

Champignon plans to biosynthesize psilocybin within the first three months of conducting laboratory experiments, with the objective of achieving optimized and scaled production of pharmaceutical-grade psilocybin for deployment in clinical settings. This strategy includes:

  • Alternative medicine (psilocybin) IP aggregation
  • Development of cGMP formulations of bioactive compounds extracted from plants and Fungi
  • Drafting of benchmark SOPs (Standard Operating Procedures)
  • Patient aggregation, focusing on veterans

Defining a New Asset Class: Psychedelic-Inspired Medicines

In the third quarter of 2020, Champignon – through clinical trials, a compelling IP portfolio and clinical pipeline and drug development platform – plans to advance its pursuit of treatments underpinned by psychedelic substances. This strategy is broken down into two ties:

  • Non-Hallucinogenic Medicines
    • Microdosing Psilocybin/LSD
    • MDMA, commonly known as ecstasy
  • Hallucinogenic Medicines
    • Psilocybin high dose
    • LSD high dose

Partnerships

Companies worldwide are beginning to incorporate functional mushrooms into their product offerings, taking advantage of growing consumer awareness of known health benefits of the ingredients found in mushrooms.

Champignon in November 2019 entered into a distribution partnership with Eurolife Brands Inc. (CSE: EURO), a leading global markets cannabis brand empowering the medical, recreational and CPG cannabis industry worldwide through a data-driven CBD marketplace supported by exclusive and unbiased physician-backed cannabis education and detailed consumer analytics. Under the agreement, Champignon’s branded products are integrated into Eurolife’s e-commerce platform, along with potential distribution opportunities in select brick-and-mortar retail locations in Europe.

Champignon also has an R&D/production formulation agreement with Drip Coffee Social Ltd., located in Nanaimo, British Columbia, which calls for the infusion of Champignon’s proprietary mushroom extract blend into a suite of cold brew coffee products and signature in-house formulations.

Leadership

Gareth Birdsall, CEO, Corporate Secretary and Director
Gareth Birdsall has more than seven years of experience working in diverse agricultural roles such as the cultivation of various fungi, in particular Cordycepes, Reishi, Lions Mane and Chaga. He is an attendee of the British Columbia Institute of Technology, studying marketing management and finance.

Steven Brohman, CPA, CFO
Steven Brohman has more than 10 years of experience working in a variety of roles with public and private companies. He has had extensive training in the audit of publicly traded companies on the TXS, TSX Venture Exchange and OTC markets, and serves as CFO and director of various public and private companies. Brohman has a bachelor’s degree of business administration and obtained his Chartered Professional Accountant designation.

Jerry Habuda, Director
Jerry Habuda brings to Champignon over 35 years of expertise in law enforcement and specialized units. From 1977 to 2012, he served as a police officer with the Toronto Police Department. During his tenure, he was assigned to the Major Crimes Unit, investigating robberies and home invasions. He was assigned to patrol the Toronto Community Housing projects at Jane/Finch to control drug trafficking and gun violence. Habuda was with the Warrant Unit where he tracked down and arrested wanted criminals. From 1993-1997, he was assigned to the Northwest Drug Squad on undercover and surveillance work, executing narcotic search warrants. Between 2002 and 2004, Habuda headed the Street Violence Task Force, a special unit designed to curb gun and drug violence that was terrorizing the city at the time.

Champignon Brands Inc. (CSE: SHRMF), closed Friday's trading session at $0.40, off by 3.6609%, on 184,939 volume with 143 trades. The average volume for the last 3 months is 714,483 and the stock's 52-week low/high is $0.221/$1.74.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

Sugarmade, Inc. (OTCQB: SGMD) was featured today in the 420 with CNW by CannabisNewsWire. The past few years have been great for cannabis. Advanced research into its effects on the body that has found it has plenty of medical benefits, coupled with changing attitudes towards the plant, have pushed it more into the mainstream. As a result, plenty of territories have passed legislation allowing either recreational or medical marijuana within their borders. Many more jurisdictions have cannabis legalization on the books or they are at least considering it.

Sugarmade, Inc. (SGMD) is headquartered in Monrovia, California, where the company recognizes new opportunities in the cannabis delivery space and in the market for supplies to the quick-service restaurant industry – both of which have fast-changing dynamics due to the recent outbreak of coronavirus in the United States.

The Coronavirus Cannabis Boom Market

Retailers across the nation are closing their doors and curtailing operations due to the coronavirus pandemic, inherently pinching sales. In the California cannabis sector, however, business has never been better – especially relative to home delivery.

California’s cannabis industry continues to operate, and media reports reveal booming cannabis sales as the state’s citizens stay home to wait out current events. The Los Angeles Times recently published the headline, “Marijuana Sales on Fire amid Virus Outbreak; New York Post “Cannabis sales hit new highs”; USA Today “American Stock Up on Pot” Fox News “California marijuana sales surge”; and ABC News Cannabis Shops thrive in coronavirus pandemic.

The state of California benefits from the ultra-high taxes paid by the highly regulated cannabis industry, and has thus deemed cannabis companies as “essential” businesses, allowing for full operations to continue. While pot shops are seeing strong foot traffic, the real growth action is in-home delivery as consumers seek to embrace social distancing. Many delivery operators are reporting difficulty in meeting demand with sales growth of up to 10% sequentially each week. It is certainly a boom time for the industry.

Sugarmade Growth Strategy

Recognizing new investment and operational opportunities within California’s cannabis market, Sugarmade is strategizing to take advantage of opportunity specifically in delivery services (non-storefront retailer), manufacturing via co-branding, and selective genetic cultivation. The company is taking a highly selective approach, targeting only the best of these opportunities for company growth.

In line with this strategy is northern California delivery service Budcars, in which Sugarmade owns a 40% interest and an option to gain a controlling interest. Budcars connects consumers with premium products sourced from top-tier farms and extractors, offering a curated menu of fully compliant cannabis products. The company maintains a competitive advantage by sourcing premium cannabis offerings and same-day delivery. In addition to maintaining its own cars, California licenses, and fulfillment center, Budcar orders its premium products in bulk at lower prices, enabling the company to rein in costs and maintain competitive pricing for its customers. Currently serving major communities within the metropolitan area of Sacramento, Budcars plans to continue the expansion of the company’s delivery reach.

Sugarmade plans to continue its expansion into burgeoning new sectors of the cannabis market through the following avenues:

  • Geographic expansion of Budcars delivery scope
  • New delivery geographies
  • Cannabis cultivation as a key component of a hybrid vertical integration strategy
  • Product technology expansion—including products containing exotic and lesser-known cannabinoids

 

Diversified Portfolio

Sugarmade has positive market exposure to cannabis delivery, as well as to the restaurant industry, at a time when these businesses are being force to move toward take-out and delivery models in order to survive.

The company has various business operations in diverse marketplaces, including food, safe packaging and sanitary supplies for various industries, and agricultural supplies. Sugarmade entered the industrial hemp and CBD space by investing in Hempistry, Inc., a privately held Nevada corporation. Hempistry began planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 5,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3% of THC, the psychoactive ingredient found in cannabis.

CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high-quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30%-40% of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Market Opportunity

There is little doubt among industry participants, and recently confirmed by Forbes, that California is the single largest cannabis market in the world. The state is expected to produce more than $3.5 billion in cannabis sales during 2020, with growth topping 23% annually. The global industrial hemp market size was estimated at $4.71 billion in 2019 and is expected to register a revenue-based CAGR of 15.8% over the forecast period of 2016-2027, according to Grandview Research. Market growth drivers include the 2018 Farm Bill and society’s increasing knowledge of the benefits of hemp products.

Overall industry growth is great, but specific vertical sector growth is even better. Cannabis delivery is clearly the fastest growing sector of the marketplace and with coronavirus fears the already robust growth rate has accelerated.

Sugarmade seems to be in the right industry at the right time in history.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick-service restaurant industry, which merged with Sugarmade in 2014.

Dedicated to getting the highest caliber of THC and CBD to its customers’ door, the company’s priority is to ensure that they receive the highest quality cannabis product free from logistical hassles. Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base.

Sugarmade, Inc. (SGMD), closed Friday's trading session at $0.0023, off by 4.1667%, on 31,594,526 volume with 250 trades. The average volume for the last 3 months is 64,261,054 and the stock's 52-week low/high is $0.001599999/$0.021999999.

Recent News

chart

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX.V: VIVO) (OTCQX: VVCIF) was featured today in the 420 with CNW by CannabisNewsWire. In December 2018, Congress passed the 2018 Farm Bill, a landmark legislation that legalized the cultivation and sale of industrial hemp and it’s derivatives after decades of prohibition. Cannabidiol, a hemp extract with medical capabilities, quickly grew in popularity, resulting in an unregulated market worth millions of dollars in sales. For months, advocates, stakeholders, and some lawmakers have urged the U.S. Food and Drug Administration (“FDA”) to create a comprehensive regulatory structure for the industry.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed Friday's trading session at $0.18045, up 2.3238%, on 137,802 volume with 37 trades. The average volume for the last 3 months is 128,212 and the stock's 52-week low/high is $0.109999999/$0.432339996.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex Inc. (NASDAQ: GNPX) was featured today in a publication from BioMedWire, examining how, since the outbreak of COVID-19, a lot of industries have come to a standstill and most institutions and research centers have scrambled to look for ways to control and curb this deadly pandemic. Interestingly, the pandemic has also brought a lot of regrets to some inventors. The regret comes as a result of not owning the rights of their inventions, especially now when the whole world is struggling to fight the virus.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Friday's trading session at $3.69, off by 3.4031%, on 1,443,718 volume with 4,070 trades. The average volume for the last 3 months is 2,804,933 and the stock's 52-week low/high is $0.231000006/$7.0300002.

Recent News

chart

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR)

The QualityStocks Daily Newsletter would like to spotlight Energy Fuels Inc. (UUUU).

Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR), based in Lakewood, Colorado, is the country’s largest producer of uranium and the leading conventional producer of vanadium, both designated by the U.S. government as critical minerals.

As the leading U.S. diversified uranium miner, Energy Fuels’ uranium production portfolio stands apart in the world. Energy Fuels has more uranium production facilities, more production capacity, and more in-ground resources than any other company in the United States. In fact, the company’s assets have produced over one-third of all U.S. uranium over the past 15 years and is uniquely positioned to increase production to meet new demand.

Energy Fuels utilizes both conventional and in-situ recovery (“ISR”) technology to produce uranium from three strategic facilities:

  • White Mesa Mill in Utah (conventional) has a licensed capacity of over 8 million pounds of U3O8 per year. The highly strategic White Mesa Mill is the only conventional uranium mill in the country and is proximate to some of the largest and highest-grade uranium mines and projects in the U.S., including the Company’s Canyon mine, La Sal Complex, Henry Mountains Complex and Roca Honda Project. White Mesa Mill provides Energy Fuels with significant production scalability as uranium demand increases. The White Mesa Mill also has other diverse businesses, including vanadium, rare earth elements (REE’s), alternate feed materials recycling and land cleanup, all described below.
  • Nichols Ranch Plant (ISR) is located in the productive Powder River Basin district of Wyoming and has a total licensed capacity of 2 million pounds of U3O8 per year. Nichols Ranch has produced 1.2 million pounds of U3O8 since commissioning in 2014, and it has significant future expansion potential from 34 fully licensed wellfields containing significant in-ground uranium resources.
  • Alta Mesa Plant (ISR) is located on over 200,000 acres of private land in Texas. The fully licensed and constructed ISR project has a total operating capacity of 1.5 million pounds of uranium per year and produced nearly 5 million pounds of U3O8 between 2005 and 2013. This low-cost production facility is currently on standby, maintained in a state of readiness to respond to expected increases in demand.

In addition to being the largest uranium miner in the U.S., Energy Fuels’ overall portfolio also includes a pipeline of high-quality, large-scale exploration and development projects that are permitted or are in advanced stages of permitting, as well as an industry-leading U.S. NI 43-101 Mineral Resource portfolio.

FACTOID: Energy Fuels has led industry efforts over the past two-plus years to get the U.S. government to recognize the importance of domestically produced uranium, including the 2018 – 2019 Uranium Section 232, the ongoing Nuclear Fuel Working Group and the recently announced creation of the U.S. strategic uranium reserve. The U.S. is by far the largest consumer of uranium in the world, yet we import almost all of our requirements; Energy Fuels aims to change that.

Nuclear Market Potential

Multiple studies in top scientific journals have shown that nuclear power is cleanest and most economical way to produce reliable electricity as worldwide demand continues to soar. Nuclear power is presently the only available and affordable low-carbon power source that can meet both current and future baseload electricity demands while simultaneously reducing air pollution and mitigating climate change. U.S. nuclear power plants currently generate nearly 20% of the nation’s electricity overall and 55% of its carbon-free electricity and even a modest increase in electricity demand would require significant new nuclear capacity by 2025. According to the World Nuclear Association (WNA), there are currently 441 operable reactors, with another 54 units under construction and 439 in various stages of planning; in addition, the WNA has identified a potentially massive supply/demand gap through 2040 of 1 billion pounds. These factors among others are expected to significantly drive increased demand for uranium.

Reasons Nuclear is Gaining Traction

  • Nuclear reactors emit no greenhouse gases during operation. Over their full lifetimes, they result in comparable emissions to renewable forms of energy such as wind and solar.
  • Unlike any other form of energy, the waste from nuclear energy is contained and managed securely. Used fuel is currently being safely stored for ultimate disposal or future reprocessing, and 96% of this waste can potentially be recycled.
  • Greater demand for clean electricity to power everything from homes to automobiles, reducing dependence on fossil fuels.

No. 1 U.S. Producer of Vanadium in 2019

Energy Fuels also produces vanadium as a byproduct of uranium production. Vanadium is designated a critical mineral, essential to the economic and national security of the United States. Energy Fuels was the largest producer of vanadium in the U.S. in 2019, and has significant high-grade, in-ground vanadium resources, as well as a separate high-purity vanadium production circuit at their White Mesa Mill, which is also the only conventional vanadium mill in the country. Crucial for use in the steel, aerospace, and chemical industries, vanadium plays a critical role in the production of high-strength and light-weight metallic alloys and demand is expected to increase across the globe.

Energy Fuels has several fully permitted and developed standby mines containing large quantities of high-grade vanadium, along with uranium, including:

  • La Sal Complex (Utah)
  • Whirlwind Mine (Colorado/Utah)
  • Rim Mine (Colorado)

Vanadium has also gained increased attention as a catalyst in next-generation high-capacity, “community-scale” batteries used for energy storage generated from renewable sources. Demand is only expected to grow as this market expands. With recent upgrades in its vanadium production operations, in 2019 Energy Fuels produced commercial levels of the highest purity (99.7%) vanadium in the mill’s history and can rapidly adjust production to meet volatile market conditions. Energy Fuels is one of the very few known avenues that provides investors access the vanadium market.

Rare Earth Element (REE) Production, Alternate Feed Material Recycling, and Land Cleanup

The White Mesa Mill also provides the company with diverse cashflow generating opportunities. Security of supply for Rare Earth Elements (REEs) supporting U.S. military and defense requirements is a major issue today. Energy Fuels has been approached by a number of entities, including the U.S. government, inquiring about the potential to process certain REEs at the mill. The White Mesa Mill is currently licensed to process certain REEs, including tantalum and niobium. And, early indications are that the mill can be utilized to produce several other REEs. The White Mesa Mill is also the only facility in North America licensed and capable of recycling alternate feed materials (AFMs). AFMs are essentially low-level waste materials that contain recoverable quantities of natural (or unenriched) uranium. The Company typically generates between $5 and $15 million per year from AFM recycling. Finally, Energy Fuels is seeking to become involved in the cleanup of legacy Cold War era uranium mines in the Four Corners region of the U.S., including on the Navajo Nation. The U.S. Environmental Protection Agency (EPA) has access to over $1.5 billion for the cleanup of just a fraction of the sites on the Navajo Nation. The White Mesa Mill is fully licensed to receive much of this material, we are one of the government’s lowest cost options, and we have the ability to recycle the material and produce usable uranium from it.

Management Team

Mark S. Chalmers, President and CEO
Mark S. Chalmers is the president and chief executive officer of Energy Fuels, a position he has held since Feb. 1, 2018, following his role as chief operating officer of Energy Fuels from July 1, 2016 – Jan. 31, 2018. From 2011 to 2015, Chalmers served as executive general manager of Production for Paladin Energy Ltd., a uranium producer with assets in Australia and Africa, including the Langer Heinrich and Kayelekera mines where, as head of operations, he oversaw sustained, significant increases in production while reducing operating costs. He also possesses extensive experience in in situ recovery (“ISR”) uranium production, including management of the Beverley Uranium Mine owned by General Atomics (Australia), and the Highland mine owned by Cameco Corporation (USA). Chalmers has also consulted to several of the largest players in the uranium supply sector, including BHP Billiton, Rio Tinto, and Marubeni, and until recently served as the chair of the Australian Uranium Council, a position he held for 10 years. Chalmers is a registered professional engineer and holds a Bachelor of Science in Mining Engineering from the University of Arizona.

W. Paul Goranson, COO
W. Paul Goranson is the chief operating officer for Energy Fuels. Goranson has 30 years of mining, processing and regulatory experience in the uranium extraction industry that includes both conventional and in-situ recovery (“ISR”) mining, and he is a registered professional engineer. Prior to the acquisition by Energy Fuels of Uranerz Energy Corporation, Goranson served as president, chief operating officer and director for Uranerz, where he was responsible for operations of the Nichols Ranch ISR Uranium Project. In addition to those duties, he also managed uranium marketing, regulatory and government affairs, exploration and land. Prior to joining Uranerz, Goranson served as president of Cameco Resources, where he led the operations at the Smith Ranch-Highland, Crow Butte and North Butte ISR uranium recovery facilities. Goranson also served as vice president of Mesteña Uranium LLC, and he has served in senior positions with Rio Algom Mining, (a subsidiary of BHP Billiton), and Uranium Resource Inc. Goranson has a Bachelor of Science in Natural Gas Engineering from Texas A&I University, and a Master of Science in Environmental Engineering from Texas A&M University-Kingsville.

David C. Frydenlund, CFO, General Counsel, Corporate Secretary
David C. Frydenlund is chief financial officer, general counsel, and corporate secretary of Energy Fuels. His responsibilities include oversight of all legal matters relating to the company’s activities. His expertise extends to NRC, EPA, state and federal regulatory and environmental laws and regulations. From 1997 to 2012, Frydenlund was vice president of regulatory affairs, general counsel and corporate secretary of Denison Mines Corp., and its predecessor International Uranium Corporation (“IUC”). He also served as a director of IUC from 1997 to 2006 and CFO of IUC from 2000 to 2005. From 1996 to 1997, Frydenlund was vice president of the Lundin Group of international public mining and oil and gas companies, and prior thereto was a partner with the Vancouver law firm of Ladner Downs (now Borden Ladner Gervais) where his practice focused on corporate, securities and international mining transactions law. Frydenlund holds a bachelor’s degree in business and economics from Simon Fraser University, a master’s degree in economics and finance from the University of Chicago and a law degree from the University of Toronto.

Curtis H. Moore, Vice President of Marketing and Corporate Development
Curtis H. Moore is the vice president of Marketing and Corporate Development for Energy Fuels. He oversees product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over 12 years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Moore is a licensed attorney in the State of Colorado. He holds Juris Doctor and MBA degrees from the University of Colorado at Boulder, and a Bachelor of Arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California.

 

Energy Fuels Inc. (UUUU), closed Friday's trading session at $1.87, up 1.0811%, on 3,226,496 volume with 6,669 trades. The average volume for the last 3 months is 1,501,060 and the stock's 52-week low/high is $0.779999971/$2.3499999.

Recent News

chart

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Friday's trading session at $15.74, off by 1.0063%, on 230,151 volume with 1,909 trades. The average volume for the last 3 months is 1,652,293 and the stock's 52-week low/high is $1.472/$19.25.

Recent News

chart

Trxade Group Inc. (NASDAQ: MEDS)

The QualityStocks Daily Newsletter would like to spotlight Trxade Group Inc. (NASDAQ: MEDS).

Trxade Group Inc. (NASDAQ: MEDS) is an integrated pharmaceutical services company that offers a unique combination of a web-based purchasing platform (www.trxade.com) for transactions between independent pharmacists and drug distributors (B2B); a network of pharmacies with E-Hub software; a mail order pharmacy; and warehouse and drug delivery services. This synergistic combination of product offerings and superior data analytics is poised to benefit all stakeholders and consumers within the pharmaceutical industry.

Trxade will leverage and scale its fully integrated model to execute the following growth strategies:

  • Increase share of pharmacist drug purchasing
  • Additional SKUs and expand product breath
  • Partner with Specialty and International Mfg.
  • Expand mail order licenses to all 50 states
  • Scale Delivmeds for consumer delivery nationwide
  • Integration with telemedicine
  • M&A Opportunities within drug value chain

Founded in 2010 and headquartered in Tampa, Florida, Trxade’s overarching corporate strategy is to penetrate the existing retail independent pharmacy marketplace and diversify the company’s pharmaceutical mix with additional specialty and acute care products. Trxade is advancing on this mission by focusing on three key niches in the health care market.

Business-to-Business (B2B)

The $330 billion U.S. pharmaceutical industry is comprised of more than 65,000 pharmacy facilities and 1,500 state-licensed suppliers. Roughly 24,000 of these facilities are independent pharmacies, which collectively spend approximately $93 billion a year on branded and generic drugs.

Trxade targets these independent pharmacies, leveraging a robust, “E-Bay/Kayak-like” technology platform with optimum buyer/seller pricing algorithms, product availability, and predictive data analytics features.

Trxade currently serves and transacts with more than one-third (10,250) of these independent pharmacies and facilitates over $10 million of drug purchases a month!

Consumer

Trxade also targets the “consumer side” of the pharmaceutical industry, aiming to lower prescription drug costs by attacking the inefficient value chain; offering drug price transparency and efficient buying; and, delivering drugs DIRECT to independent pharmacists and consumers.

The company operates a full-service mail order pharmacy for U.S. consumers, as well as a mobile app called “Delivmeds” (http://www.delivmeds.com) which enables SAME DAY home delivery of dispensed prescriptions.

Retail

Trxade’s Managed Services Organization (“TrxadeMSO”) enables its member independent retail pharmacies to get patients, process orders, and deliver or ship prescriptions to patients. TrxadeMSO provides access to encompassing network of pharmacies through the E-Hub software, allowing for timely and comprehensive medication fulfillment.

These offerings ensure the best-suited pharmacy receives the patient’s information, thereby ensuring appropriate medication coverage based on the patient’s location, payor coverage, and medication access/inventory. This will save the clinicians and their staff time as they benefit from efficiency and enhanced workflow management in script processing and fulfillment.

Health Care Market

The U.S. health care market currently hovers near $4 trillion and is expected to grow as the general population ages. This growth will have greater impact on consumers as out-of-pocket expenses also rise. Additionally, drug costs are paced to increase faster than the overall health care and well above inflation.

Drug pricing is variable, and reimbursement is squeezing profits. This provides significant opportunity for the Trxade model of price visibility and profit optimization.

Trxade’s fair online market platform targets the nation’s retail community and independent pharmacies, of which there are approximately 24,000 nationwide. TRxADE has found that independent pharmacies, in order to be cost-effective, often operate with minimal staff and conduct up-to-the minute price checks. The TRxADE S2P platform gives these pharmacists the ability to easily compare the price of drugs offered by various suppliers and select the most favorable deals, saving money by taking advantage of best purchase pricing.

TRxADE’s programs include:

  • TRxADE Exchange, which opens and widens the distribution channel to the retail, community pharmacy. A purchasing pharmacy can view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. This approach significantly enhances the competitive spirit of the exchange where the lowest price exists for each product at any given point in time. TRxADE has become a competitive tool for all progressive entities and is recognized for its easy searching of hard-to-find generic pharmaceuticals at substantially reduced prices.  
  • RX Guru™ is an industry-leading price prediction model that integrates product shortage insight into pharmacy acquisition benchmarks (“PAC”) to ascertain trends and pricing variances that result in significant purchasing opportunities. RX Guru affords members the opportunity to continuously benefit from real price purchasing opportunities that are concealed from the rest of the industry. 
  • Product Shortage Database – TRxADE maintains the most comprehensive retail, specialty and acute care pharmaceutical product shortage database in the country. Other industry competitors mainly restrict their efforts to specialty and acute care product shortages and narrowly research oral generic products. TRxADE’s advanced prediction tools help members source those hard-to-find products at affordable costs in a timely and easy-to-search process. 

Management Team 

Trxade’s management team is rich in expertise within the pharmaceutical supply chain and is supported by a base of advisors and contractors who are experts in related fields of the pharmaceutical sector.

Suren Ajjarapu – Chairman of the Board, Chief Executive Officer and Secretary
Suren Ajjarapu has served as Trxade’s chairman of the board, CEO and secretary since 2014, and as the chairman of the board, chief executive officer and secretary of Trxade Nevada since its inception. Ajjarapu also serves as a chairman of the board for Feeder Creek Group Inc., since March 2018. Ajjarapu formerly was a founder, CEO and chairman of Sansur Renewable Energy Inc., a company involved in developing wind power sites in the Midwest, United States; a founder, president and director of Aemetis Inc., a biofuels company (AMTX.OB); a founder, chairman and CEO of International Biofuels, a subsidiary of Aemetis Inc.; and a co-founder, COO, and director at Global Information Technology Inc., an IT outsourcing and systems design company. Ajjarapu holds an M.S. in environmental engineering from South Dakota State University, Brookings, South Dakota, and an MBA from the University of South Florida, specializing in international finance and management. Ajjarapu is also a graduate of the Venture Capital and Private Equity program at Harvard University.

Prashant Patel – Director, President and Chief Operating Officer
Prashant Patel has served as Trxade’s full-time president and COO, and as a director since the company’s acquisition of Trxade Nevada in 2014, and as the COO and president and as a director of Trxade Nevada since its inception. He has been a president and member of the board of Trxade since August 2010. Patel is a registered pharmacist and pharmaceutical consultant with over 10 years of experience in retail pharmacy and pharmaceutical logistics. He is the founder of several pharmacies in the Tampa Bay area, in Florida. Since 2008, Patel has been managing member of the APAA LLC pharmacy. Since 2007, Patel has been a vice president of Holiday Pharmacy Inc. Patel graduated from Nottingham University School of Pharmacy and practiced in the United Kingdom before obtaining his masters in Transport, Trade and Finance from Cass Business School, City University, UK.

Trxade Group Inc. (MEDS), closed Friday's trading session at $6.04, off by 3.5144%, on 6,325 volume with 67 trades. The average volume for the last 3 months is 52,707 and the stock's 52-week low/high is $3.29999995/$11.6000003.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.